2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

EPICAn™

Biomedical EcoSystem development office in Taiwan, BEST

July 24th (Fri) 21:10 - 22:40 Entrepreneur Pitch 4

EPICAnTM

Company Info

Name /EPICAnTM

Address /250 Wu-Hsing Street, Taipei city, Taiwan

Website /

Presenter

Name /Sheng-Chao Wang

Title /Ph.D. Student

Email /wsc0327@gmail.com

Telephone /(Work) +886-2-27361661 ext.6183

Fax /+886-2-27361661 ext.6162

Mobile /+886-978-315760

Company Type

Biotechnology

About the Company

EPICAnTM is a healthcare company focused on commercializing early cancer detection with liquid biopsies. We promise“easy to Predict, We can”. We use the real-time methylation-specific PCR by checking three hypermethylated gene biomarkers of plasma’s cell-free DNA to be a high accurate detection of breast cancer. We have established an automatic process. The result could provide clinicians an early intervention suggestion to improve early diagnosis confidence. We can and we will detect cancer easily and quickly.

Brief Description of main products or services

An automatic blood test for the early detection of breast cancer.

Our aim is to supply a new non-invasive, rapid, accurate, and precise screening test for breast cancer.

  • Low-invasive: Blood-based test.
  • Accuracy: The technique reveals a high-accuracy early detection model for breast cancer with a sensitivity of 93.0%, a specificity of 93.0%, AUC of 0.930.
  • Rapid: The ccfDNA extraction and chemically modification in one machine shortening the process to complete within 5 hours.
  • Precision: Automatic process to reduce artificial errors.
  • Global markers: We identified biomarkers in Taiwanese and TCGA breast cancer patients using genome-wide methylation array and next evaluated in paired 109 tumors and normal tissues of breast cancer patients and 342 plasma specimens.
  • Other clinical applications:
    (1) Combined analysis with mammography and ultrasonography can lower the false-positive rate of breast cancer screening.
    (2) Treatment response monitoring: The aberrant methylated ccfDNA biomarkers are disappeared when followed by surgery and adjuvant treatment.
  • Patents: Done filed PCT and Taiwan patent application
  • Company objectives: Raise capital for
    (1) A prototype for the testing kit enable to reach to 1000 clinical sample size;
    (2) GMP manufacturer OEM production;
    (3) Apply for TFDA and FDA approval.

Contact Person

Name /Sheng-Chao Wang (Ace)

Email /wsc0327@gmail.com

Phone /+886-978-315760